SANN Santhera Pharmaceuticals

Santhera Publishes Agenda for its Annual General Meeting

Santhera Publishes Agenda for its Annual General Meeting

Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on May 20, 2025, at 10:00 CEST at Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Switzerland.

The invitation to the AGM with agenda items and explanations will be sent to registered shareholders by mail and can be viewed on Santhera’s website at

Agenda (Overview)

  1. Approval of the Annual Report, Annual Financial Statements and the Consolidated Financial Statements 2024
  2. Appropriation of the Annual Result and Offset of Deficit
  1. Consultative Vote on the Compensation Report 2024
  2. Discharge of the Members of the Board of Directors and of the Executive Management from Liability for the Financial Year 2024
  3. Conditional Capital for Employee Participations and Amendment to the Articles of Incorporation
  4. Election of a new Member & Re-election of two Members of the Board of Directors and of the Chairman of the Board
  5. Re-election of the Members of the Nomination & Compensation Committee
  6. Approval of the Compensation of the Members of the Board of Directors
  7. Approval of the Compensation of the Members of the Executive Management
    1. Re-election of the Statutory Auditors
    2. Re-election of the Independent Proxy



      About Santhera Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Medicines Agency (EMA), in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), in China by the National Medical Products Administration (NMPA) and Hong Kong by the Department of Health (DoH). Santhera has out-licensed rights to AGAMREE for North America to Catalyst Pharmaceuticals and for China and certain countries in Southeast Asia to Sperogenix Therapeutics. For further information, please visit . AGAMREE® is a trademark of Santhera Pharmaceuticals.   For further information please contact:   Catherine Isted, Chief Financial Officer:   ICR Healthcare       Disclaimer / Forward-looking statements This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements. # # #  

Attachment



EN
29/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Santhera Pharmaceuticals

 PRESS RELEASE

Santheras Aktionäre stimmen an der heutigen Generalversammlung allen A...

Santheras Aktionäre stimmen an der heutigen Generalversammlung allen Anträgen des Verwaltungsrats zu Pratteln, Schweiz, 20. Mai 2025 - Santhera Pharmaceuticals (SIX: SANN) gibt heute bekannt, dass die Aktionäre an der heutigen Generalversammlung (GV) in Pratteln, Schweiz, allen Anträgen des Verwaltungsrates mit grosser Mehrheit zugestimmt haben. Die teilnehmenden Aktionäre vertraten insgesamt 5’073’050 Aktien oder 37,5% des Aktienkapitals des Unternehmens. Genehmigung des Jahresberichts 2024 und Entlastung der Organe Die Aktionäre genehmigten den Jahresbericht, die Jahresrechnung und die ...

 PRESS RELEASE

Santhera’s Shareholders Approve all Board Proposals at Today’s Annual ...

Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting Pratteln, Switzerland, May 20, 2025 – Santhera Pharmaceuticals (SIX: SANN) today announces that its shareholders approved all motions by the Board of Directors at the Annual General Meeting (AGM) held today in Pratteln, Switzerland, with a large majority. Participating shareholders represented a total of 5,073,050 shares or 37.5% of the Company’s share capital. Approval of the 2024 Annual Report and discharge of corporate bodies The shareholders approved the Annual Report, the annual financial statements ...

 PRESS RELEASE

Santhera veröffentlicht Einladung zur ordentlichen Generalversammlung

Santhera veröffentlicht Einladung zur ordentlichen Generalversammlung Pratteln, Schweiz, 29. April 2025 - Santhera Pharmaceuticals (SIX: SANN) hat heute die Einladung zur ordentlichen Generalversammlung (GV) veröffentlicht, die am 20. Mai 2025 um 10:00 Uhr MESZ im Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Schweiz, stattfinden wird. Die Einladung zur Generalversammlung mit den Traktanden und Erläuterungen wird den eingetragenen Aktionären per Post zugestellt und kann auf der Website von Santhera unter eingesehen werden. Traktanden (Überblick) Genehmigung des Geschäftsberichts, d...

 PRESS RELEASE

Gesamtjahresergebnisse für das am 31. Dezember 2024 endende Jahr

Gesamtjahresergebnisse für das am 31. Dezember 2024 endende Jahr Ein Jahr des Wandels nach der erfolgreichen Einführung von AGAMREE® Pratteln, Schweiz, 29. April 2025 - Santhera Pharmaceuticals (SIX: SANN) gibt heute die Ergebnisse für das am 31. Dezember 2024 abgeschlossene Geschäftsjahr bekannt. Dario Eklund, CEO von Santhera, sagte: "Das Jahr 2024 war für Santhera eine Zeit des Wandels mit der erfolgreichen Einführung von AGAMREE® zur Behandlung von Duchenne-Muskeldystrophie in Deutschland und Österreich sowie in den USA durch unseren Lizenzpartner Catalyst Pharmaceuticals. Santhera be...

 PRESS RELEASE

Santhera Publishes Agenda for its Annual General Meeting

Santhera Publishes Agenda for its Annual General Meeting Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on May 20, 2025, at 10:00 CEST at Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Switzerland. The invitation to the AGM with agenda items and explanations will be sent to registered shareholders by mail and can be viewed on Santhera’s website at Agenda (Overview) Approval of the Annual Report, Annual Financial Statements and the Consolidated Financial Statements 202...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch